US Market for Dental Biomaterials Will See Strong Growth, Reaching a Value of Over $485 Million by 2022 Product Innovations and Strategic Initiatives Will Spur Greater Adoption of these Products, According to Millennium Research Group
TORONTO, Dec. 10, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, dental biomaterial procedure volumes will see strong growth, spurred largely by rising use of dental implants; bone grafting, which uses one or more biomaterial products, is commonly performed before the placement of an implant. Increased marketing and awareness of the benefits of biomaterials among physicians and patients, as well as a growing emphasis on aesthetics, will also drive adoption.
This market will be further supported by product innovations that will promote incorporation of dental biomaterial into more procedures. For example, demineralized bone matrices (DBMs) are increasingly being offered with added cancellous bone chips, which offer additional structural properties for bone growth as well as radiopacity. Zimmer and Keystone Dental were previously the only competitors to offer this product feature, but Biomet released the RegenerOss Allograft Putty Plus earlier this year.
Another strategic initiative is Straumann's new packaging of its Emdogain product, which competes in the tissue regeneration segment. Rather than offering one large syringe, the new Emdogain 015 will contain five smaller syringes, each filled with 0.15 mL of the product. This configuration will make the product more cost effective for smaller defects and soft tissue grafting procedures, where much of the content of a large syringe would be wasted.
"Although the synthetic bone graft substitute (BGS) segment has historically seen slow adoption, this segment will see strong growth as research and development initiatives increase with the improving economy and as more clinical trials begin to show noninferiority of synthetics to current industry standards," said MRG Analyst David Lee. "As a result, more competitors are entering this space, including ACE Surgical Supply, RTI Biologics and DENTSPLY International. These companies are poised to gain share at the expense of smaller companies, such as NovaBone Products and Kerr. Although these companies have previously held strong shares in the synthetic BGS market, they will struggle against these new entrants because the latter have established customer bases and more resources to designate to research and development."
Millennium Research Group's US Markets for Dental Biomaterials 2014 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for BGS, dental membranes and tissue regeneration products in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Millennium Research Group